MIDAZOLAM clinical trials

A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG908 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors

This study is testing a new drug, TNG908, for people with advanced cancers that have a specific genetic change called MTAP-deleted. It aims to see if the drug is safe, what dose works best, and if it can help shrink tumours.

SAFETY AND PHARMACOKINETICS OF ODM-208 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

This study looks at a new drug, ODM-208, for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. It checks if the drug is safe, what dose works best, and how it moves through the body.

Randomized, multi-center, double-blind, two-armed, parallel active groups, prospective trial, to evaluate, in pediatric population undergoing 'Calcaneo stop' surgery or Inguinal hernia repair, the efficacy and safety of chloroprocaine 1% and 2% for peripheral nerve block based on concentration-response relationships.

This study is looking at how well two different strengths of a medicine called chloroprocaine work to numb pain during common childhood surgeries, like `Calcaneo stop` or hernia repair. We want to find the best and safest dose for children.

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

This study looks at a new drug, erdafitinib, for people with a type of bladder cancer called urothelial cancer that has spread or can't be removed by surgery. It aims to see how well it works and if it's safe, specifically for those with certain genetic changes in their cancer.

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

This study is testing a new drug, neladalkib, for advanced cancers that have a specific genetic change called ALK rearrangement. It's looking at how safe the drug is and if it shrinks tumours in people with certain types of lung cancer and other solid tumours.

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

This study looks at two drug combinations, inavolisib with fulvestrant, and alpelisib with fulvestrant, for advanced breast cancer that has specific genetic changes and has already been treated with certain therapies. It aims to see which combination works better and is safer.

Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer

This study is looking into a new medicine, ODM-208, for men with prostate cancer that has spread and is resistant to standard treatments. It aims to see how safe the drug is, what side effects it might cause, and how the body handles it.

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

This study is testing a new drug, PF-07220060, for people with advanced cancers like breast, prostate, and lung cancer. Researchers want to see if it's safe and how it works, both by itself and with other cancer medicines.

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

This study looks into new ways to treat advanced stomach and gut cancers called GIST. It compares a new drug called CGT9486 (bezuclastinib) combined with an existing drug, sunitinib, against sunitinib alone, to see which works better for patients who haven't responded well to other treatments.

A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

This study is for adults with advanced cancer that has a specific KRAS gene change. It tests new medicines, BI 1823911 alone and with BI 1701963, to see if they can shrink tumours. Currently, there are no other successful treatments.

Midazolam and mORPHine to alleviate symptoms at the End of life in patients on acUte geriatric wardS (MORPHEUS study)

The MORPHEUS study looks at how well two medicines, morphine and midazolam, help make older patients in their last days of life more comfortable. Researchers are checking the doses used, how they're given, and any side effects like sickness or restlessness, to improve care at this difficult time.

EVALUATION OF OPIOID CONSUMPTION USING OBJECTIVE NOCICEPTIVE MONITORING IN PATIENTS INDICATED FOR DEEP SEDATION IN THE INTENSIVE CARE UNIT

This study looks at how different sedatives affect very ill patients in intensive care, particularly focusing on how much pain relief medication they need. It aims to find the best ways to keep patients comfortable and safe while reducing side effects.

ADRESS : Efficacy of the Alpha 2 agonist dexmedetomidine for sympathetic Deactivation in REfractory Septic Shock: a randomized, controlled trial

This study looks at a medicine called dexmedetomidine for severe blood poisoning (septic shock). Researchers want to see if it helps reduce symptoms and improve survival compared to usual treatments. It's a key step to understand if this medicine can become a new option for patients.

A Global Multicenter, Randomized, Double-blinded, Propofol-controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of HSK3486 Injectable Emulsion for Induction of General Anesthesia in Adults Undergoing Elective Surgery